Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024

By sjmartinez • August 7, 2024

Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir J. Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093/cid/ciae405. Epub ahead of print. PMID: 39107255.

Tags: COVID-19 severity, COVID-19 vaccine effectiveness, JN.1 and BA.2.86, Publications, Pulmonary, Critical Care & Sleep Medicine, SARS-CoV-2 variants, test-negative design

Clinical phenotypes in acute and chronic infarction explained through human ventricular electromechanical modelling and simulations

Zhou X, Wang ZJ, Camps J, Tomek J, Santiago A, Quintanas A, Vazquez M, Vaseghi M, Rodriguez B. Clinical phenotypes in acute and chronic infarction[...]

Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

Nguyen T, Koric A, Chang CE, Barul C, Radoi L, Serraino D, Purdue MP, Kelsey KT, McClean MD, Negri E, Edefonti V, Moysich K, Zhang[...]

Expert Perspective: Management of Relapses in Giant Cell Arteritis

Alba MA, Unizony S, Warrington KJ, Murgia G, Prieto-González S, Salvarani C, Matteson EL, Kermani TA. Expert Perspective: Management of Relapses in Giant Cell Arteritis.[...]